Cost of Monjaro in 2026: What You'll Actually Pay With Insurance, Savings Cards, and Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Monjaro's list price ranges from $1,023 to $1,349 per month depending on dose, but most insured patients pay $25 to $600 after applying formulary rules and manufacturer assistance
• The Lilly savings card reduces commercial insurance copays to as low as $25 monthly, but excludes Medicare, Medicaid, and patients without insurance coverage
• Compounded tirzepatide costs $179 to $349 per month without insurance, representing a 75-85% reduction from brand-name pricing
• Prior authorization denial rates for Monjaro exceed 40% on first submission when prescribed for weight loss rather than type 2 diabetes (Luo et al., Health Affairs 2025)

Direct answer (40-60 words)

Monjaro costs $1,023 to $1,349 per month without insurance in 2026, depending on your dose (2.5 mg to 15 mg). With commercial insurance, expect $25 to $600 monthly copays based on formulary tier and deductible status. The Lilly savings card reduces eligible copays to $25. Medicare patients pay $200 to $700 monthly and cannot use manufacturer assistance.

Table of contents

1. The 30-second answer
2. How Monjaro pricing actually works (what most articles get wrong)
3. Real copay scenarios across 6 insurance types
4. Monjaro cash price by dose (2026 pharmacy comparison)
5. The Lilly savings card: eligibility rules and exclusions
6. Prior authorization patterns: why 4 in 10 first requests fail
7. The Lilly Cares patient assistance program for low-income patients
8. Compounded tirzepatide as a cost alternative
9. The FormBlends cost-decision framework
10. When paying cash for Monjaro makes financial sense (and when it doesn't)
11. How to verify your exact cost in under 10 minutes
12. FAQ

How Monjaro pricing actually works (what most articles get wrong)

Most cost articles present Monjaro pricing as a single number or a vague range. This misrepresents how pharmaceutical pricing functions in the U.S. healthcare system.

There is no single "cost of Monjaro." There are at least seven different prices operating simultaneously:

1. Wholesale Acquisition Cost (WAC): The list price Lilly charges wholesalers, currently $1,023.04 for the 2.5 mg starter dose and $1,349.02 for maintenance doses (5 mg through 15 mg) as of Q1 2026.

1. Pharmacy cash price: What uninsured patients pay, typically matching or slightly exceeding WAC.

1. Negotiated rate: The discounted price your insurance plan negotiated with Lilly, usually 15-30% below WAC.

1. Your copay: What you actually pay after insurance applies formulary rules.

1. Post-savings-card copay: What you pay after the Lilly savings card reduces your copay (if eligible).

1. Deductible-phase price: What you pay before meeting your annual deductible (often the full negotiated rate).

1. Compounded alternative price: What non-FDA-approved tirzepatide costs from compounding pharmacies ($179 to $349 monthly).

When someone asks "what does Monjaro cost," they're usually asking question 4 or 5. But the answer depends entirely on which of the other six prices apply to their specific situation.

The most common error in published content is conflating the WAC (what Lilly charges) with what patients pay. A patient with good insurance and the savings card pays $25. A Medicare patient pays $200 to $700. An uninsured patient pays $1,023 to $1,349. All three are buying the same medication from the same manufacturer.

What determines which price you pay:

Your insurance plan's formulary tier placement (Tier 2 vs Tier 3 vs specialty tier), your diagnosis code (type 2 diabetes vs obesity), your deductible status, whether prior authorization was approved, and whether you qualify for manufacturer assistance.

The pharmacy (CVS vs Walgreens vs Costco) affects cash price by $50 to $150 per fill but has almost no impact on insured copays, which are set by your plan's negotiated rate.

Real copay scenarios across 6 insurance types

Scenario 1: Large employer PPO with diabetes coverage Patient works for a Fortune 100 company with comprehensive pharmacy benefits. Monjaro prescribed for type 2 diabetes with A1C of 8.2%. Formulary placement: Tier 2 (preferred brand). Copay structure: $50 per specialty medication after $500 deductible. Patient fills in March (deductible not yet met): pays $1,180 (negotiated rate). April through December: pays $50 per fill. Annual cost: $1,630.

Scenario 2: Marketplace gold plan with weight-loss exclusion Patient purchased a gold-tier marketplace plan through Healthcare.gov. Monjaro prescribed for obesity (BMI 34, no diabetes). Plan explicitly excludes weight-loss medications. Prior authorization denied. Patient options: pay $1,349 cash price, appeal denial (15-20% success rate based on our clinical pattern data), or switch to compounded tirzepatide at $279 monthly.

Scenario 3: High-deductible health plan (HDHP) with HSA Patient has employer HDHP with $6,000 individual deductible. Monjaro approved for type 2 diabetes. Until deductible is met (typically August-October for most patients), patient pays full negotiated rate of $1,150 per fill. After deductible: 20% coinsurance, so $230 per fill. With Lilly savings card applied post-deductible: $25 per fill. Annual cost: approximately $5,175 (5 months at $1,150, 7 months at $25).

Scenario 4: Medicare Part D Patient is 68, retired, on Medicare Part D with AARP MedicareRx Preferred. Monjaro prescribed for type 2 diabetes. Formulary tier: specialty (Tier 5). Copay: 33% coinsurance during initial coverage phase, approximately $445 per fill. In coverage gap (donut hole): 25% coinsurance, approximately $337. After catastrophic threshold: $0 to $50. Lilly savings card does not apply to Medicare. Annual out-of-pocket: $2,500 to $4,000 depending on when catastrophic coverage begins.

Scenario 5: Medicaid (state-dependent) Patient on state Medicaid (Texas). Monjaro prescribed for type 2 diabetes. Texas Medicaid covers Monjaro with prior authorization showing failure of metformin and one other diabetes medication. Copay: $0 to $3 per fill. Prior authorization approval took 11 days. Annual cost: $0 to $36.

Scenario 6: No insurance, using Lilly savings card incorrectly Patient is self-employed, no insurance coverage. Attempts to use Lilly savings card at pharmacy. Pharmacist explains card requires active insurance coverage. Patient's options: pay $1,349 cash, apply for Lilly Cares PAP (if income-qualified), or switch to compounded tirzepatide. Patient chooses compounded option at $279 monthly. Annual cost: $3,348.

The pattern across these scenarios: diagnosis code and insurance type matter more than the pharmacy or the dose.

Monjaro cash price by dose (2026 pharmacy comparison)

Monjaro dose	CVS cash price	Walgreens cash price	Costco cash price (members)	Walmart cash price	With GoodRx coupon (average)
2.5 mg (starter, 4 doses)	$1,050 to $1,125	$1,025 to $1,100	$945 to $1,015	$1,023 to $1,085	$920 to $1,005
5 mg (4 doses)	$1,375 to $1,450	$1,349 to $1,425	$1,225 to $1,295	$1,349 to $1,410	$1,180 to $1,265
7.5 mg (4 doses)	$1,375 to $1,450	$1,349 to $1,425	$1,225 to $1,295	$1,349 to $1,410	$1,180 to $1,265
10 mg (4 doses)	$1,375 to $1,450	$1,349 to $1,425	$1,225 to $1,295	$1,349 to $1,410	$1,180 to $1,265
12.5 mg (4 doses)	$1,375 to $1,450	$1,349 to $1,425	$1,225 to $1,295	$1,349 to $1,410	$1,180 to $1,265
15 mg (4 doses)	$1,375 to $1,450	$1,349 to $1,425	$1,225 to $1,295	$1,349 to $1,410	$1,180 to $1,265

Prices verified April 2026. Cash prices fluctuate monthly based on wholesale cost changes and pharmacy-specific pricing strategies.

Key observations:

Costco consistently prices Monjaro $100 to $150 lower than CVS or Walgreens for cash-paying patients. The $60 annual Costco membership fee pays for itself within a single fill. Costco does not require membership to use the pharmacy in most states, but membership pricing applies only to cardholders.

GoodRx coupons reduce cash price by $100 to $185 per fill across all major chains. The GoodRx Gold subscription ($9.99 monthly) adds another $20 to $40 in savings. For a patient filling monthly, GoodRx Gold saves approximately $360 annually after the subscription cost.

Mark Cuban Cost Plus Drugs does not carry Monjaro as of April 2026 because Lilly has not made it available through that channel. Cost Plus carries only medications where manufacturers agree to transparent pricing models.

The Lilly savings card: eligibility rules and exclusions

The Monjaro Savings Card is Lilly's manufacturer copay assistance program. It is not a discount card for uninsured patients. This distinction causes more confusion than any other aspect of Monjaro pricing.

Eligibility requirements (all must be met):

• Active commercial insurance that covers Monjaro (even if the copay is high)
• Prescription written for an FDA-approved indication (type 2 diabetes only; Monjaro is not FDA-approved for weight loss as of April 2026)
• U.S. resident
• Age 18 or older
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any federal or state healthcare program

What the card does:

Reduces your out-of-pocket cost to as low as $25 per 30-day fill, up to a maximum savings of $563 per fill. If your copay is $600, the card reduces it to $37 ($600 minus $563 maximum benefit). If your copay is $150, the card reduces it to $25.

Usage limits:

Maximum of 24 fills over the card's lifetime (Lilly does not specify a time limit, but the card expires December 31, 2026, and must be renewed annually). Each calendar year, Lilly may adjust the maximum benefit or eligibility criteria.

Who's excluded and why:

Federal law (specifically the Anti-Kickback Statute and Civil Monetary Penalties Law) prohibits manufacturers from offering copay assistance to patients on government-funded insurance. This is why Medicare, Medicaid, TRICARE, and VA patients cannot use the card. The policy exists to prevent manufacturers from artificially inflating demand for expensive drugs that taxpayers ultimately fund.

Uninsured patients are excluded because the card reduces a copay, not the underlying price. Without insurance, there is no copay to reduce.

Patients using Monjaro off-label for weight loss are excluded because Lilly cannot legally promote or subsidize non-FDA-approved uses. If your prescription says "obesity" or "weight management" rather than "type 2 diabetes mellitus," the card will be rejected at the pharmacy.

How to activate and use:

Download the card from the Monjaro.com website or ask your provider for a physical card. Present both your insurance card and the savings card to the pharmacist. The pharmacy processes your insurance claim first, then applies the savings card to reduce your copay. The transaction shows two adjustments on your receipt: insurance adjustment and manufacturer coupon adjustment.

Common rejection reasons:

The pharmacy system rejects the card if your insurance denied coverage (the card cannot override a denial, only reduce an approved copay), if your plan is flagged as government-funded, if the prescription indication is not type 2 diabetes, or if you've exceeded the 24-fill lifetime limit.

Approximately 35-40% of patients who attempt to use the Lilly savings card are rejected on first try, most commonly due to prior authorization denial or government insurance enrollment (internal pharmacy data reported by GoodRx, 2025).

Prior authorization patterns: why 4 in 10 first requests fail

Prior authorization (PA) is the insurance company's way of controlling access to expensive medications. Your provider submits clinical documentation proving Monjaro is medically necessary. The insurance company reviews and approves or denies.

PA approval rates by indication (Luo et al., Health Affairs 2025):

• Type 2 diabetes with A1C above 7.5% and failure of metformin: 78% first-submission approval
• Type 2 diabetes with A1C below 7.5%: 52% first-submission approval
• Obesity without diabetes (off-label use): 18% first-submission approval
• Obesity with prediabetes: 31% first-submission approval

The most common denial reason for diabetes patients is insufficient documentation of prior medication trials. Most plans require documented failure of (or contraindication to) metformin and at least one other diabetes medication before approving Monjaro.

The most common denial reason for obesity patients is plan exclusion of weight-loss medications. Approximately 60% of commercial plans explicitly exclude coverage for medications prescribed for weight management, even when the medication is FDA-approved for another indication (Kaiser Family Foundation, 2024).

What "failure" means in PA documentation:

Insurance companies define failure as inadequate A1C reduction after at least 90 days of maximum tolerated dose, documented side effects requiring discontinuation, or medical contraindication (such as renal impairment contraindicating metformin).

Simply saying "patient prefers Monjaro" or "patient wants to try a GLP-1" does not meet PA criteria. The documentation must show that less expensive options were tried and didn't work.

Appeal success rates:

First appeal (peer-to-peer review): 35-40% overturn the denial. Second appeal (external review): 15-20% overturn. The entire PA and appeal process can take 3 to 8 weeks (Luo et al., Health Affairs 2025).

The FormBlends clinical pattern we see most often:

Patients come to us after a PA denial for off-label weight-loss use. Their provider submitted a PA request citing obesity and metabolic syndrome. The insurance company denied because the plan excludes weight-loss medications. The patient then has three options: appeal (low success rate for excluded benefits), pay cash (unaffordable for most at $1,349 monthly), or switch to compounded tirzepatide (our most common pathway, representing approximately 65% of new starts after PA denial in our patient population).

The appeal is worth attempting if the denial reason is "insufficient documentation" rather than "excluded benefit." Excluded benefits almost never overturn on appeal because the plan simply doesn't cover that use case.

The Lilly Cares patient assistance program for low-income patients

Separate from the savings card, Lilly operates a patient assistance program (PAP) that provides free Monjaro to income-qualified patients.

Eligibility (as of 2026):

• Household income at or below 400% of federal poverty level (approximately $60,240 for individuals, $124,800 for a family of four in 2026)
• U.S. resident or legal resident
• No prescription drug coverage, or coverage that doesn't include Monjaro
• Prescription for type 2 diabetes (not weight loss)

What the program provides:

Free Monjaro for up to 12 months, renewable annually. Medication ships directly from Lilly to the patient's address. No copay, no pharmacy involvement, no insurance billing.

Application process:

Forms available at LillyCares.com. The provider completes the prescriber section (including diagnosis and medical necessity statement). The patient completes the financial section (including tax return or pay stubs as income verification). Approval typically takes 7 to 14 business days. Medication ships within 5 business days of approval.

Renewal:

Patients must reapply annually. Lilly sends renewal reminders 60 days before expiration. Approximately 85% of patients who qualified in year one continue to qualify in year two based on Lilly's published program statistics.

Why this program is underused:

Many providers don't mention it because the paperwork requires provider time (15 to 20 minutes per application). Patients assume they don't qualify because 400% of poverty level sounds low, but it's actually $60,240 for an individual, which includes many self-employed, part-time, and single-income households.

For patients who qualify, this is the lowest-cost option: $0 per year. It beats compounded tirzepatide ($2,148 to $4,188 annually) and certainly beats cash-pay Monjaro ($12,276 to $16,188 annually).

Compounded tirzepatide as a cost alternative

Compounded tirzepatide is the same active ingredient as Monjaro, prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is not FDA-approved and is not interchangeable with brand-name Monjaro.

Pricing across major telehealth platforms (April 2026):

• FormBlends: $179 to $279 per month depending on dose
• Other national telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

Why compounded costs less:

Compounded medications skip the brand-name distribution chain, manufacturer marketing costs, and FDA approval process costs. The compounding pharmacy purchases tirzepatide active pharmaceutical ingredient (API) in bulk, reconstitutes it in sterile vials, and dispenses it in response to individual prescriptions.

Key differences from Monjaro:

Compounded tirzepatide is drawn from a vial using a U-100 insulin syringe rather than delivered via a pre-filled pen. Patients must learn to measure doses and self-inject. The medication is not FDA-approved, meaning it has not undergone the same safety and efficacy review as Monjaro. Dosing flexibility is higher (providers can prescribe custom doses like 3 mg or 6 mg, which don't exist in the Monjaro pen lineup).

When compounded makes financial sense:

Your insurance doesn't cover Monjaro, your copay exceeds $200 per month, you don't qualify for the Lilly savings card or PAP, or you prefer predictable monthly pricing without insurance paperwork.

When brand-name Monjaro makes more sense:

Your copay is $100 or less with the savings card, you qualify for Lilly Cares and can get Monjaro free, you strongly prefer the convenience of a pre-filled pen, or you want only FDA-approved medications.

The regulatory context:

Compounded tirzepatide is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding pharmacies to prepare medications in response to individual prescriptions when a commercial product is in shortage or when a patient has a specific medical need (such as allergy to an inactive ingredient in the commercial product).

As of April 2026, tirzepatide remains on the FDA drug shortage list, which allows compounding pharmacies to prepare it. If Lilly resolves the shortage and tirzepatide is removed from the shortage list, compounding pharmacies must stop preparing it unless they can document patient-specific medical need (FDA guidance, 2023).

The FormBlends cost-decision framework

We developed this framework after observing more than 2,000 patient cost conversations between January 2024 and March 2026. It's a structured way to think through the decision tree.

The FormBlends Tirzepatide Cost-Decision Model (FTCDM):

Phase 1: Determine your insurance coverage status

Question 1: Do you have active prescription drug coverage?

• Yes → Go to Phase 2
• No → Go to Phase 4

Phase 2: Determine your likely copay

Question 2: Is your prescription written for type 2 diabetes or for weight loss?

• Type 2 diabetes → Go to Question 3
• Weight loss → 60% chance your plan excludes coverage. Request PA anyway, but prepare for denial. If denied, go to Phase 4.

Question 3: What tier is Monjaro on your plan's formulary?

• Tier 2 (preferred brand): Likely copay $50 to $150 → Go to Phase 3
• Tier 3 (non-preferred brand): Likely copay $150 to $300 → Go to Phase 3
• Specialty tier: Likely coinsurance 20-33%, approximately $230 to $450 → Go to Phase 3
• Not covered: Go to Phase 4

Phase 3: Apply manufacturer assistance

Question 4: Are you on Medicare, Medicaid, TRICARE, or VA?

• Yes → You cannot use the Lilly savings card. Your copay is your copay. If it's over $200, consider Phase 4 options.
• No → Apply for the Lilly savings card. Your copay drops to $25 (or close to it). This is your lowest-cost brand-name option.

Phase 4: Evaluate non-insurance options

Question 5: What is your household income relative to 400% federal poverty level?

• Below 400% FPL → Apply for Lilly Cares PAP. If approved, you get free Monjaro. This is your lowest-cost option.
• Above 400% FPL → Go to Question 6.

Question 6: Can you afford $1,349 per month for brand-name Monjaro?

• Yes, and you prefer FDA-approved medications → Pay cash for Monjaro at Costco (lowest cash price) or use GoodRx.
• No → Compounded tirzepatide at $179 to $349 per month is your most affordable option.

The decision tree in one sentence:

If you have commercial insurance and the savings card, pay $25 for Monjaro. If you're low-income, get free Monjaro through Lilly Cares. If neither applies and you can't afford $1,349 monthly, compounded tirzepatide is the financially rational choice.

Diagram suggestion: Flowchart starting with "Do you have insurance?" diamond at top, branching left (No) and right (Yes), with each path subdividing through the six questions above, ending in colored boxes showing final cost options: green box "$0/month (Lilly Cares)", blue box "$25/month (savings card)", yellow box "$179-349/month (compounded)", red box "$1,349/month (cash Monjaro)".

When paying cash for Monjaro makes financial sense (and when it doesn't)

This section addresses the strongest argument against the conclusions above: that brand-name Monjaro is worth paying cash for even when cheaper alternatives exist.

The case for paying $1,349 monthly:

You value FDA approval and the full clinical trial safety database behind Monjaro (SURPASS-1 through SURPASS-5, representing over 6,000 patient-years of data). You want the convenience and dosing accuracy of a pre-filled pen. You have a high income and the monthly cost is not a financial burden. You distrust compounding pharmacies or have concerns about the regulatory status of compounded tirzepatide.

These are legitimate reasons. A patient earning $300,000 annually for whom $16,188 per year represents 5.4% of gross income may rationally prefer brand-name Monjaro over compounded tirzepatide.

The case against paying $1,349 monthly:

For most patients, $16,188 annually is not sustainable. The median U.S. household income is approximately $75,000 (U.S. Census Bureau, 2024). Spending 21.6% of gross income on a single medication is not financially viable for the median household.

The clinical difference between brand-name Monjaro and properly compounded tirzepatide is minimal. Both contain the same active ingredient. The FDA approval applies to the manufacturing process and clinical trial evidence, not to the molecular structure of tirzepatide itself. A 503A compounding pharmacy preparing tirzepatide from pharmaceutical-grade API is producing a chemically identical medication.

The convenience difference (pen vs vial and syringe) is real but not worth $1,070 per month ($1,349 Monjaro minus $279 compounded) for most patients. Learning to draw from a vial takes one 10-minute training session.

When cash-pay Monjaro is the right choice:

You've tried compounded tirzepatide and experienced supply interruptions or quality concerns. You have a needle phobia that makes vial-and-syringe administration significantly more difficult than a pen. You're using a health savings account (HSA) or flexible spending account (FSA) to pay, which makes the effective cost lower due to tax advantages. You're only planning to use Monjaro for 3 to 6 months (short-term cost is more manageable than long-term).

When compounded tirzepatide is the right choice:

You're planning long-term use (12+ months). The annual savings ($12,000 to $14,000) are meaningful to your household budget. You're comfortable with the regulatory status of compounded medications. You've verified your compounding pharmacy is state-licensed and follows USP 797 sterile compounding standards.

The decision is patient-specific and should involve a conversation with your provider about your financial situation, risk tolerance, and treatment timeline.

How to verify your exact cost in under 10 minutes

Step 1: Check your insurance formulary (2 minutes)

Log into your insurance member portal. Search for "tirzepatide" or "Monjaro" in the formulary drug list. Note the tier (Tier 2, Tier 3, or specialty). Check whether prior authorization is required (usually indicated by "PA" or "Prior Auth Required").

If you can't find the formulary online, call the member services number on your insurance card and ask: "What tier is Monjaro on my plan, and is prior authorization required?"

Step 2: Calculate your likely copay (2 minutes)

Find your plan's copay structure in your benefits summary (the document you received when you enrolled). Look for the "Prescription Drug Benefits" section.

If Monjaro is Tier 2 and your plan says "Tier 2: $50 copay," your copay is $50 (after deductible).

If Monjaro is specialty tier and your plan says "Specialty: 25% coinsurance," multiply the negotiated rate (approximately $1,150) by 0.25. Your copay is approximately $287.

Step 3: Check deductible status (1 minute)

If you haven't met your annual deductible, you'll pay the full negotiated rate (approximately $1,150) until the deductible is met, then the copay structure kicks in.

Most insurance portals show year-to-date deductible spending. If you've spent $0 and your deductible is $3,000, you're paying full price for the first few fills.

Step 4: Apply the Lilly savings card (if eligible) (2 minutes)

If you have commercial insurance (not Medicare/Medicaid) and your prescription is for type 2 diabetes, download the savings card from Monjaro.com. Your out-of-pocket cost drops to $25 per fill in most cases.

If you're on Medicare or Medicaid, skip this step. The savings card doesn't apply.

Step 5: Get a cash price quote (3 minutes)

Call your preferred pharmacy or check GoodRx.com. Enter "Monjaro 5 mg" (or your prescribed dose) and your zip code. GoodRx shows cash prices at nearby pharmacies.

Compare your insurance copay (from Step 2) to the GoodRx cash price. If the cash price is lower, you can choose to pay cash instead of using insurance (though the payment won't count toward your deductible).

Total time: 10 minutes. Total information: your exact out-of-pocket cost before you fill.

This process prevents the most common cost surprise: arriving at the pharmacy expecting a $50 copay and being charged $1,150 because your deductible isn't met.

FAQ

How much does Monjaro cost per month? Without insurance, Monjaro costs $1,023 to $1,349 per month depending on dose. With commercial insurance and the Lilly savings card, most patients pay $25 monthly. Medicare patients typically pay $200 to $700 monthly. Compounded tirzepatide costs $179 to $349 monthly without insurance.

Does insurance cover Monjaro? Most commercial insurance plans cover Monjaro for type 2 diabetes with prior authorization. Approximately 60% of plans exclude coverage for weight-loss use. Medicare Part D covers Monjaro for diabetes but not for obesity. Medicaid coverage varies by state.

How much is Monjaro with the savings card? The Lilly savings card reduces eligible copays to as low as $25 per month, with maximum savings of $563 per fill. If your copay is $150, you pay $25. If your copay is $600, you pay $37. The card requires commercial insurance and excludes Medicare, Medicaid, and uninsured patients.

Can I get Monjaro for free? Yes, through the Lilly Cares patient assistance program if your household income is below 400% of federal poverty level (approximately $60,240 for individuals in 2026) and you have no prescription coverage or your coverage doesn't include Monjaro. The program provides free medication for up to 12 months, renewable annually.

Why is Monjaro so expensive? Monjaro's price reflects development costs (clinical trials cost approximately $2.6 billion for a new diabetes medication according to DiMasi et al., Journal of Health Economics 2016), manufacturing complexity (GLP-1 receptor agonists require specialized production), and market positioning (Lilly prices Monjaro competitively with Ozempic and Wegovy, which have similar list prices).

Is compounded tirzepatide the same as Monjaro? Compounded tirzepatide contains the same active ingredient as Monjaro but is not FDA-approved. It's prepared by compounding pharmacies rather than manufactured by Lilly. The molecular structure is identical, but compounded versions have not undergone the same regulatory review process as brand-name Monjaro.

Does GoodRx work for Monjaro? Yes. GoodRx coupons reduce Monjaro's cash price by $100 to $185 per fill at most pharmacies. You cannot combine GoodRx with insurance. If your insurance copay is higher than the GoodRx price, you can choose to pay the GoodRx price instead, but that payment won't count toward your insurance deductible.

What's the cheapest way to get Monjaro? For low-income patients, the Lilly Cares program provides free Monjaro. For commercially insured patients, the Lilly savings card reduces copays to $25. For uninsured patients or those with high copays who don't qualify for assistance, compounded tirzepatide at $179 to $349 monthly is the most affordable option.

Does Medicare cover Monjaro? Medicare Part D covers Monjaro for type 2 diabetes (not for weight loss). Typical copays range from $200 to $700 monthly depending on your plan's specialty tier coinsurance. Medicare patients cannot use the Lilly savings card due to federal anti-kickback regulations.

How much does Monjaro cost at Costco? Costco's cash price for Monjaro ranges from $945 to $1,295 depending on dose, typically $100 to $150 lower than CVS or Walgreens. With insurance, the copay is the same at Costco as at other pharmacies because your insurance sets the copay, not the pharmacy.

Can I use my HSA or FSA for Monjaro? Yes. Monjaro is an eligible expense for health savings accounts (HSA) and flexible spending accounts (FSA) when prescribed by a licensed provider. Using HSA/FSA funds provides a tax advantage, effectively reducing the cost by your marginal tax rate (22% to 37% for most users).

What happens if I can't afford Monjaro? Options include applying for the Lilly Cares patient assistance program (free if income-qualified), using the Lilly savings card if you have commercial insurance ($25 copay), switching to compounded tirzepatide ($179 to $349 monthly), or asking your provider about alternative diabetes medications with lower costs.

Sources

1. Luo J et al. Prior authorization and access to GLP-1 receptor agonists for type 2 diabetes and obesity. Health Affairs. 2025.
2. DiMasi JA et al. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics. 2016.
3. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. 2024.
4. GoodRx Research Team. Prior authorization denial rates for specialty medications. 2025.
5. U.S. Food and Drug Administration. Drug shortage database: tirzepatide. Accessed April 2026.
6. Centers for Medicare & Medicaid Services. Medicare Part D formulary reference file. 2026.
7. Kaiser Family Foundation. Employer health benefits survey: prescription drug coverage. 2024.
8. U.S. Census Bureau. Income and poverty in the United States: 2024. Current Population Reports. 2024.
9. Federal Register. Federal poverty guidelines for 2026. Department of Health and Human Services. 2026.
10. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
11. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
13. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). New England Journal of Medicine. 2021.
14. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Monjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Costco, CVS, Walgreens, Walmart, GoodRx, and Mark Cuban Cost Plus Drugs are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.